Table 1.

Designs of the included studies

	EXCLAIM 2010	MAGELLAN 2013	APEX 2016	MARINER 2018
Authors	Hull et al15	Cohen et al14	Cohen et al16	Spyropoulos et al13
Year of publication	2010	2013	2016	2018
Setting	International, multicenter	International, multicenter	International, multicenter	International, multicenter
Study design	Randomized parallel placebo-controlled trial	Randomized active comparator–controlled trial	Randomized active comparator–controlled trial	Randomized placebo-controlled trial
Blinding	Double blind	Double blind	Double blind, double dummy	Double blind
Cancer status	Active cancer or history of cancer	History of cancer or active cancer	History of cancer or active cancer	History of cancer in the past 5 y
	Excludes intracranial neoplasm or metastasis	Excludes intracranial neoplasm or metastasis	Excludes intracranial neoplasm or metastasis, active lung cancer with residual disease, and nonmelanoma skin cancer	Excludes all active cancers and nonmelanoma skin cancer
Intervention	40 mg enoxaparin SC daily for 10 ± 4 d then enoxaparin 40 mg SC daily for additional 28 ± 4 d	10 mg rivaroxaban daily for 35 ± 4 d	80 mg betrixaban orally daily for 35-42 d (loading dose, 160 mg); reduced-dose betrixaban (40 mg) for patients with severe renal insufficiency or receiving concomitant P-glycoprotein inhibitor	10 mg rivaroxaban daily for 45 d after discharge
Control	40 mg enoxaparin SC daily for 10 ± 4 d then placebo for additional 28 ± 4 d	40 mg enoxaparin SC daily for 10 ± 4 d	40 mg enoxaparin SC daily for 10 ± 4 d	Placebo for 45 d after discharge

SC, subcutaneous.